title: Lonidamine in non-small-cell lung cancer: a phase II study.
abstract: The activity of lonidamine (a derivative of indazole-carboxylic acid and a new drug with a characteristic antitumor activity) was evaluated in non-small-cell lung cancer (NSCLC). Twenty-five patients with NSCLC with or without prior treatment received lonidamine at the dose of 450 mg/daily p.o. up to progression. Objective responses obtained were: 3 (12%) partial responses and 3 (12%) minor responses with a mean duration of 13.7 weeks for partial responses. Mean duration of treatment was 20 weeks (range 4-97+). During to the drug's characteristics, bone marrow toxicity was not observed; myalgia and mild testicular pain were the most significant side effects.
authors.affiliation: Medical Oncology Dept, Civil Hospital, Sassari, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Contu
authors.forename: N A
authors.initials: NA
authors.lastname: Olmeo
authors.forename: P
authors.initials: P
authors.lastname: Pani
authors.forename: A
authors.initials: A
authors.lastname: Deriu
authors.forename: S
authors.initials: S
authors.lastname: Ortu
authors.forename: C
authors.initials: C
authors.lastname: Paga
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use* / Q000633:toxicity; D008099:Liver / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; C016371:lonidamine